StockData
XTL Biopharmaceuticals Ltd logo

XTL Biopharmaceuticals Ltd (XTLB) stock

XTLBNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026Score 0/30
$1.62+0.08 (+5.19%)

Close on Nov 17, 2026Market cap $15.33MP/E –Yield –

XTL Biopharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2024 it was $451.00K.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$451.00K–

More XTL Biopharmaceuticals figures

See a number that looks wrong?